
OPCH Stock Forecast & Price Target
OPCH Analyst Ratings
Bulls say
Option Care Health is well positioned for growth with increased revenue and adjusted EPS expected in Q4. The company's expanded repurchase program and strong relationships with healthcare providers and payors also bode well for future success. However, a potential narrowing of networks by insurers and changes in government reimbursement, as well as potential risks with M&A and the growth of biosimilars, could pose challenges for the company's future growth and margins.
Bears say
Option Care Health is expected to see negative impacts from Stelara-related profit headwinds in 2026, as the medication will be subject to the Inflation Reduction Act and biosimilar conversions. However, the company's diverse portfolio and strong cash flows provide potential upside from capital deployment and a de-risked product portfolio. Despite raising the target multiple to 14x, a higher multiple is warranted due to minimal future downside from Stelara beyond 2026 and increased portfolio transparency, resulting in a Price Target of $38 and a Market Outperform rating.
This aggregate rating is based on analysts' research of Option Care Health and is not a guaranteed prediction by Public.com or investment advice.
OPCH Analyst Forecast & Price Prediction
Start investing in OPCH
Order type
Buy in
Order amount
Est. shares
0 shares